Hello everyone! It’s been a while since my last blog update, but I feel extremely compelled to share some updates with a stock that I believe is extremely undervalued at the moment. The stock I’m referring to is RISING BIOSCIENCES (RSII trading at .011). Many of you may remember that I brought this stock to your attention in mid 2017 along with its “sister stock” PAOG (formerly NWAV).

Rising India, Inc., (“RSII”), operating as Rising Biosciences, Inc. is a research and development company focusing on oral and topical cannabis and non-cannabis based pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. To date they have developed several products including TSW Topicals (www.TSW-topicals.com), a range of over-the-counter, topical pain relief products using an innovative blend of clinically proven organic ingredients such as menthol, curcumin, ginger and capsaicin to reduce inflammation and effectively relieve pain. These products include solutions for muscle and joint pain, back pain, neuropathy/nerve pain and arthritis. TSW Pain, a topical pain relief cream for muscle and joint relief. Additionally, the have new novel peptide scar cream that is shown to deliver amazing results for post surgical use or tissue scar injuries. They are currently working with a company for national distribution of its Scar Peptide Serum.

Though the above products can be large revenue generators, the main product the company set out for since inception and that has me excited with tremendous potential is there Cannophen trademarked compound. Below, The COO of Rising Biosciences shares his extremely positive results with their Cannophen product. Additionally, Cannophen is now being offered at Alternative Centers of America in Ohio the partner company. Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures.

Below are some quotes from recent press releases by Rising Biosciences COO- Art Hall:

1- “We are also thrilled to announce that included in a line of medical cannabis products, the company is debuting Cannophen™, a revolutionary product we’ve been developing for some time now. Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific tirpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures. This allows patients to take their medicine by swallowing a flavorless capsule, just like any other oral medication

2- We are also pleased to announce a new MMJ version of the TSW pain cream containing Cannabidiol (CBD).”

Hall adds, “There has never been any proper way to dose with the above said methods. We have developed Cannophen™ using the strictest quality and control standards and methods set forth in the pharmacy compounding industry using experienced chemists and veteran pharmacists.”

This is a monumental event for our company and one that means quite a bit to me personally,” states COO Arthur Hall. “I have been using Cannophen™ since its earliest development stages in hopes to explore and discover its beneficial properties. Initially I was taking for symptoms of Parkinson’s and was astounded by overall results: I had also been battling cancer for some time and through surgery, limited chemotherapy and the use of Cannophen™ I am now cancer free. My physicians are okay with the continued use of Cannophen™ for maintenance. We are grateful to be sharing this with other patients beginning with the program in Ohio I also will be meeting with a Producer/Processor in California next week that has demonstrated serious interest in licensing and distributing Cannophen™ and other Rising Biosciences products.”

Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. According to The National Cancer Institute, Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.

Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. One notable study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.

This is some great data that Rising Biosciences has shared with us and from what I gather they are making Cannophen commercially available very soon. In fact, if you read the several social media posts below, you will see the company is NOW looking for a of cannabis producer/processor in California and will be announcing contracts with them shortly. If you click on the link you can see the pictures and facebook posts:

Just wanted to keep everyone posted yesterday we had a few more meetings and we will be working on letters of intent and…

Posted by Rising BioSciences, Inc. on Thursday, March 8, 2018

Rising BioSciences, Inc.
March 8 at 3:17pm ·
Just wanted to keep everyone posted yesterday we had a few more meetings and we will be working on letters of intent and contracts when we get back to Ohio and we have a meeting with another group this afternoon we will keep you posted

Rising BioSciences, Inc. added 3 new photos.
March 6 at 3:10pm ·
Had a great meeting with one of the premiere producer processors in Southern California stay tuned for more information


The exciting part everyone needs to realize is that Rising Biosciences is a research and pharmaceutical development company that operates through compounding pharmacies strict laws in regards to quality and dispensing that they must abide by, but the MAJOR ADVANTAGE is they can produce and make commercially available their formulations without going through the long arduous FDA approval process that can take years to complete and can run a company tens of millions of dollars. (*But it will not be considered FDA approved unless you complete the process outlined by the FDA. ) However, if a doctor prescribes/recommends a compound formulation or product in states where cannabis is medicinally legal, Cannophen can be attained through a compounding pharmacy, or perhaps licensing agreements with distributors.  This is a growing trend we are seeing in now across the country for certain diseases and illness.

Below is a great article that you should all read. Here is the link:
Compounding Pharmacies to Compete with Pharma Manufacturers?

Lastly, I would like to say that I believe Rising Biosciences is extremely undervalued at these levels with its small market cap vs. the growing hot properties in the cannabis pharmaceutical/medicinal sector. In my trading analysis, Rising Biosciences (RSII) small float is mainly traded by technical and small profit taking minded traders. However, I strongly feel this is about to change rapidly with all the progress that has been made and recent company announcements. We have all seen stocks in the pharmaceutical/medicinal cannabis sector reach much higher levels and even multiple dollars with floats that are similar to RSII. I believe RSII time is NOW, and in my opinion it is a strong buy at these deflated prices. One final note, the CEO expects the NEW FINRA SYMBOL and the NAME CHANGE to happen shortly as he did with NWAV changing to PAOG to truly reflect the companies mission statement and business. Therefore, if there is any short position in RSII, this could force a major short squeeze in the stock as shorts and brokers would have to deliver and or cover shares.

PAO Group, PAOG also has the same CEO as Rising Biosciences, Robert Weber. This is another stock that falls into the same pattern of trading as I stated in the above paragraph. I feel this company is way undervalued as well with the major progress they have made in treating a variety of diseases with their unique customized approach, but as per the companies mission, mainly geared to opioid addicted therapies. Additionally, their expansion into several legal states with the new corporate owned centers, has lead to sharp increase in revenues reported by the company. The opioid crisis is a major problem that is happening right now in this country and is growing at an alarming rate. POAG has aligned itself in a sector that is not only much needed for this country in battling the opioid addictions, but can be very lucrative as well for shareholders.

Disclaimer: This blog is stating my opinions only coupled with information specifically released or made public by the company. I make no claims in profiting in this stock or any stock. Always do your own due diligence before investing in securities. Additionally, I receive NO compensation in any form for this blog or any blog I publish. This blog is just stating my investing opinions.